Accelerate Diagnostics (AXDX) Stock Statistics & Valuation Metrics

Accelerate Diagnostics has a market cap or net worth of $3.38M. The enterprise value is $55.21M.

Accelerate Diagnostics has 25,210,392 shares outstanding. The number of shares has decreased by -2.65% in one year.

Accelerate Diagnostics’s return on equity (ROE) is 0.89 and return on invested capital (ROIC) is -254.30%.

The current PE Ratio of Accelerate Diagnostics is -0.56. Accelerate Diagnostics’s PEG ratio is >-0.01.

In the last 12 months, Accelerate Diagnostics had revenue of 11.70M and earned -50.05M in profits. Earnings per share was -2.15.

In the last 12 months, operating cash flow was -24.19M and capital expenditures -509.00K, giving a free cash flow of -24.70M billion.

Accelerate Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Accelerate Diagnostics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Accelerate Diagnostics as a current ratio of 0.71, with Debt / Equity ratio of -118.80%

In the past 12 months, Accelerate Diagnostics has paid -66.00K in taxes.

Accelerate Diagnostics EV to EBITDA ratio is -2.37, with an EV/FCF ratio of -3.22.

Accelerate Diagnostics has $16.30M in cash and marketable securities with $66.58M in debt, giving a net cash position of $50.28M billion.

Gross margin is 23.12%, with operating margin of -301.85%, and net profit margin of -427.81%.

The average price target for Accelerate Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―